Sun Pharmaceutical Industries Limited has informed the Exchange regarding the Outcome and proceedings of the 33rd Annual General Meeting

Sun Pharmaceutical held its 33rd AGM on 31 July 2025 via video conferencing, where shareholders approved all 8 resolutions including a final dividend of Rs. 5.50 per equity share for FY25. Key board changes include Mr. Kirti Ganorkar's appointment as the new Managing Director (replacing Mr. Dilip Shanghvi, who moves to Executive Director), Ms. Vidhi Shanghvi joining as Whole-time Director, and Mr. Sudhir Valia's retirement. Chairman Dilip Shanghvi shared FY25 results: revenue grew 9% to Rs. 520 billion, EBITDA up 17.3% to Rs. 153 billion (29% margin), and adjusted net profit rose 19% to Rs. 120 billion. The company also completed the Taro acquisition, acquired Checkpoint Therapeutics, and launched Leqselvi in the US, with FY26 guidance of mid-to-high single-digit topline growth.